Although the company will continue to pursue « higher-risk, high reward » drug candidates such as pegilodecakin, these will be a smaller part of the portfolio in the future, said Chief Scientific Officer Daniel Skovronsky. Flair also analysed dozens of open letters published by alumnae of private schools who complained last year about racist abuse they had […]